

# Information Disclosure Statement by Applicant (PTO/SB/O8)

Page 1 of 4

Complete if Known

Application No.: 10/555,011

Filing Date: October 31, 2005

First Named Inventor: Nava Zisapel

Group Art Unit: 1628

Examiner Name: Jennifer M Kim

Attorney Docket No.: 2007-122

Customer No.: 6449

Confirmation No.: 9212

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	1.	4,680,172		Leeson	07-14-1987
	2.	4,765,985		Leeson	08-23-1988
	3.	4,965,074		Leeson	10-23-1990
	4.	5,284,660		Lee et al.	02-08-1994
	5.	5,508,039		Yates et al.	04-16-1996
	6.	5,641,801		Wurtman	06-24-1997
	7.	5,700,828		Federowicz et al.	12-23-1997
	8.	5,750,557		Zisapel	05-12-1998
	9.	5,872,101		Munoz et al.	02-16-1999
	10.	6,068,853		Giannos et al.	05-30-2000
	11.	6,069,138		Ponroy	05-30-2000
	12.	6,183,775	B1	Ventouras	02-06-2001
	13.	6,353,015	B1	Oxenkrug et al.	03-05-2002
	14.	6,353,051	B1	Huang	03-05-2002
	15.	6,486,172	B2	Myers et al.	11-26-2002

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

# Information Disclosure Statement by Applicant (PTO/SB/O8)

Complete if Known	
<b>Application No.:</b>	10/555,011
<b>Filing Date:</b>	October 31, 2005
<b>First Named Inventor:</b>	Nava Zisapel
<b>Group Art Unit</b>	1628
<b>Examiner Name:</b>	Jennifer M Kim
<b>Attorney Docket No.:</b>	2007-122
<b>Customer No.:</b>	6449
<b>Confirmation No.:</b>	9212

Page 2 of 4

Confirmation No.:

## U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No. <sup>1</sup>	Publication Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	16.	20010029959	A1	Burgard et al.	10-18-2001
	17.	20030051728	A1	Lloyd et al.	03-20-2003
	18.	20030062042	A1	Wensley et al.	04-03-2003
	19.	20040096118	A1	Liang	05-20-2004

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
	20.	WO	0045795	A2	CIPLA Limited	08-10-2000	
	21.	EP	0197390	A2	Societe Des Prodis Nestle S.A. Produits	10-15-1986	
	22.	EP	1272177	B1	Neurim Pharmaceuticals Limited	01/08/2003	
	23.	WO	02076211	A1	SmithKline Beecham Corporation	10-03-2002	
	24.	RU	2134108	C1	Zaslavskaja Rina Mikhajlovna	08-10-1999	
	25.	WO	8803803	A1	FORSCHUNGSGESELLSCHAFT RAUCHEN UND GESUNDHEIT MBH	06-02-1988	
	26.	WO	9307870	A1	ALZA CORPORATION	04-29-1993	
	27.	WO	9427576	A1	DANBIOSYST UK Limited	12-08-1994	
	28.	WO	9501766	A1	CYGNUS Therapeutic Systems	01-19-1995	
	29.	WO	9623496	A1	Neurim Pharmaceuticals Limited	08-08-1996	
	30.	WO	9632947	A1	ELI LILLY AND COMPANY	10-24-1996	
	31.	WO	9854189	A1	NEUROSEARCH	12-03-1998	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

# Information Disclosure Statement by Applicant (PTO/SB/O8)

		Complete if Known
	<b>Application No.:</b>	10/555,011
	<b>Filing Date:</b>	October 31, 2005
	<b>First Named Inventor:</b>	Nava Zisapel
	<b>Group Art Unit</b>	1628
	<b>Examiner Name:</b>	Jennifer M Kim
	<b>Attorney Docket No.:</b>	2007-122
	<b>Customer No.:</b>	6449
<b>Page 3 of 4</b>	<b>Confirmation No.:</b>	9212

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	32.	DINELEY et al., "Amino Acid Determinants of Alpha 7 Nicotinic Acetylcholine Receptor Surface Expression", J Biol Chem. 275(18): 13974-85, 2000, 1 page.	
	33.	DUCKLES et al., "Melatonin Receptors Potentiate Contractile Responses to Adrenergic Nerve Stimulation in Rat Caudal Artery", Proc. West. Pharmacol. Soc. 38, 1995, pp. 101-102.	
	34.	ENGELAND et al., "Nicotine and Sensory Memory in Alzheimer's Disease: An Event-related Potential Study", PubMed, Brain Cogn. 49(2); 2002, pp 232-4.	
	35.	EVANS et al., "Evidence for Direct Vasoconstrictor Activity of Melatonin in "Pressurized" Segments of Isolated Caudal Artery from Juvenile Rats", Archives of Pharmacology, 346, 1992, pp. 362-365.	
	36.	HOPE et al., "Long-Term Upregulation of Protein Kinase A and Adenylate Cyclase Levels in Human Smokers", The Journal of Neuroscience, 27(8): 2007, pp. 1964-1972.	
	37.	Levine et al., "Nicotinic Treatment for Cognitive Dysfunction", PubMed, Curr Drug Targets CNS Neurol Disorders, 2002, 1(4): 423-31.	
	38.	LIN et al., "Structure-activity Studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) Pyridine (ABT-089): An Orally Bioavailable 3-pyridyl Ether Nicotinic Acetylcholine Receptor Ligand with Cognition-enhancing Properties", J Med Chem, 40(3), 1997, pp. 385-90.	
	39.	LUBOSHIZSKY et al., "Sleep-inducing Effects of Exogenous Melatonin Administration", Sleep Medicine Reviews, Vol. 2, Issue 3, 1998, pp. 191-202.	
	40.	MOLINARI et al., "2-[125I]iodo-5-methoxycarbonylamino-N-acetyltryptamine: A Selective Radioligand for the Characterization of Melatonin ML2 Binding Sites, " Eur J Pharmacol., 301(1-3):159-68, 1996, 1 page.	
	41.	OXENKRUG, "Antidepressive and Antihypertensive Effects of MAO-A Inhibition: Role of N-acetylserotonin. A review, Neurobiology (Bp), 7(2): 1997, 1 page.	
	42.	REZVANI et al., "Cognitive Effects of Nicotine", Society of Biological Psychiatry, 2001, 49:258-267.	
	43.	ROGERS et al., "Potential Action of Melatonin In Insomnia", Sleep, Vol. 26, No. 8, 2003, pp. 1058-9.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

# Information Disclosure Statement by Applicant (PTO/SB/O8)

		<i>Complete if Known</i>
<b>Application No.:</b>		10/555,011
<b>Filing Date:</b>		October 31, 2005
<b>First Named Inventor:</b>		Nava Zisapel
<b>Group Art Unit</b>		1628
<b>Examiner Name:</b>		Jennifer M Kim
<b>Attorney Docket No.:</b>		2007-122
<b>Customer No.:</b>		6449
<b>Page 4 of 4</b>	<b>Confirmation No.:</b> 9212	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	44.	STICKGOLD et al., "Sleep, Learning, and Dreams: Off-line Memory Reprocessing", Science, Vol. 294, 2001, 1 page.	
	45.	WEEKLEY "Effects of Melatonin on Pulmonary and Coronary Vessels are exerted Through Perivascular Nerves", Clinical Autonomic Research 3, 1993, pp. 45-47.	
	46.	WETTER et al., "Tobacco Withdrawal and Nicotine Replacement Influence Objective Measures of Sleep", Journal of Consulting and Clinical Psychology, Vol. 63, No. 4, 1995, pp. 658-667.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.